All serum samples were prospectively collected at outpatient clinics and were prepared, aliquoted, and stored at -80°C within two hours. This method has been previously shown to best preserve HCV RNA, and possibly, viral particles. '5 Of the 84 patients with CH, 37 were subsequently treated with lymphoblastoid IFN (Sumiferon, Sumitomo Pharmaceuticals, Japan), six million unit (MU) daily for two weeks followed by six MU thrice weekly for 22 weeks (468 MU in total). (Table I) .
To evaluate the reproducibility of this HCV core protein assay, three positive standard samples with the low, middle and high HCV core protein level were measured, respectively (Table II) . The intra-assay and the inter-assay coefficients of variation (CV) for the standards were calculated to be within the range of 4.20-11.05% and 4.14-9.52%, respectively. For the sensitivity of the assays, among the 175 patients, 146 (83.4%) were positive by FEIA, compared with 1 1 1 (63.4%) by bDNA assay (p<001). For the specificity, all 13 controls were negative for both HCV RNA by bDNA and HCV core protein by FEIA.
In patients infected with HCV type 1, the median serum HCV core protein level was 149 (Fig 2) .
Thirty seven of 84 patients with chronic active hepatitis C were subsequently treated with IFN. Eleven (29.7%) of them showed sustained response, and 26 (70.3%) were nonresponders. There was no difference in sex (male:female=4:7 v 8:18), age (52.1 (9.2) v 53-1 (10.4)), history of blood transfusion (2 of 11 v 8 of 26) and pretreatment ALT (mean (SD)) (90.9 (45 6) v 120.7 (65.5) IUAl) between the patients showing sustained response and no response. However, the median HCV core protein level in the sustained response group (median: 36 RFI, range; <20 to 418 RFI) was significantly lower than the no response patients (338 RFI, range; 57 to 1580 RFI) (p<0 01) (Fig 3) . For In an analysis of the conservation of the HCV core amino acid sequences from all known isolates available through GenBanks, the region recognised by the monoclonal antibodies (amino acid 21-60) was shown to be highly conserved (data not shown).
There are a few possible explanations to account for the lack of correlation between serum HCV core protein and HCV RNA in patients infected with HCV type 2. Firstly, the number of patients with HCV type 2 infection was small in this study and may miss a weak correlation. Secondly, the number of HCV core proteins in HCV type 2 may be more variable or low compared with HCV type 1. As most other viruses contain a comparatively stable number of core molecules per viral particle, it is fairly safe to assume that this is the case for HCV, arguing that the quantification of HCV RNA by bDNA version 1.0 on HCV type 2 may be more variable than HCV type 1. Further studies based on large number of patients comparing FEIA and bDNA version 2-0 are required to further define the concordance between these two assays.
The finding that serum HCV core protein level in patients with HCV type 2 infection was lower than those with HCV type 1 is also in accord with previous studies using competitive RT-PCR type 2 and 3 illustrates the difficulties in developing a reliable assay for the quantification of a viraemia,'2 given the pronounced genetic heterogeneous nature of the HCV genome. bDNA assay version 2-0 was designed to tackle these problems. As this FEIA is using monoclonal antibodies that recognised highly conserved epitopes across HCV type 1 and 2, it is likely that this assay will also be very useful in quantification of HCV viraemia. A proper head to head comparison between two assays in the future may resolve this issue.
It was reported that low pretreatment HCV RNA level is a good predictor of a subsequent favourable response to IFN therapy.8 " Our finding of a significant difference in serum HCV core protein level between patients showing different subsequent response to IFN suggests that measuring serum HCV core protein level is a good alternative.
